Navigation Links
Bayer Expands Its Hemophilia Leadership Development Program
Date:2/2/2012

ing five weeks at the selected hemophilia organization, where they will gain first-hand knowledge about the work done on a local level and engage in projects building on the skills developed earlier in the program.  During the final week at Bayer, the interns will report on their experience and present a project developed with their local chapter. 

"We are very pleased that Bayer chose our chapter to participate in the newly expanded Hemophilia Leadership Development Program," said Tom Wilmarth, executive director of Hemophilia Foundation of Upstate New York – Rochester.  "We're confident our intern will gain valuable knowledge and fulfillment by supporting the hemophilia community in this way."

Bayer established the Hemophilia Leadership Development Program in 2007.  Since that time, many program participants have become more active hemophilia advocates and have gone on to careers serving the community, government and industry.    

About Hemophilia A
Hemophilia A, also known as factor VIII deficiency or classic hemophilia, is largely an inherited bleeding disorder in which one of the proteins needed to form blood clots in the body is missing or reduced. Hemophilia A, the most common type of hemophilia, is caused by deficient or defective blood coagulation proteins, known as factor VIII. Hemophilia A is characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs.  Approximately one in 5,000 males born in the United States has hemophilia.

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Medical
'/>"/>
SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phase III Data Show Bayers Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera
2. Phase 3 Data Show Bayers Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Therapi
3. Ventana Medical Systems, Inc. to Collaborate with Bayer on Companion Diagnostic Test for New Biological Cancer Therapy
4. Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI): Phase III Data on Bayers Investigational Compound Regorafenib (BAY 73-4506) in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Or
5. Intendis, Inc. Changes Name to Bayer HealthCare
6. Bayers Xarelto® (rivaroxaban) Becomes First Fixed Dose Once-Daily Anticoagulant Tablet Approved in the UK for Stroke Prevention in non-valvular Atrial Fibrillation; and the First Single Drug Regimen for Deep Vein Thrombosis
7. Bayers Drospirenone-containing Combination Oral Contraceptives: FDA Advisory Committees Affirm Positive Benefit-risk Profile and Recommend an Update of Labels to Reflect Information From Available Studies
8. Bayer HealthCare LLC Stops Trademark Infringement by Indian Pharmaceutical Company
9. Bayer HealthCare and Health Alliance Medical Plans Enter Outcomes-based Agreement
10. Bayer HealthCares MEDRAD and Nuance Communications Unveil Industrys First(1) Solution to Automate CT Contrast-Injection Documentation at the annual Radiology Society of North America (RSNA) Meeting
11. Intergraph® Technology Enables Bayer Technology Services to Engineer New Plant in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014  Nektar Therapeutics (Nasdaq: ... for the third quarter ended September 30, 2014 on ... financial markets. Howard Robin , president and chief ... the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 ... release and a live audio-only Webcast of the conference ...
(Date:10/30/2014)... --  Auxilium Pharmaceuticals , Inc. (NASDAQ: ... today announced financial results for the third quarter ... corporate, commercial, regulatory and clinical development updates from ... pleased with the continued momentum and strong performance ... this quarter, especially the XIAFLEX franchise, which more ...
(Date:10/30/2014)... Oct. 30, 2014  TWi Pharmaceuticals, Inc. today announced ... States Food and Drug Administration (FDA) on its Abbreviated ... 23 mg, the generic equivalent to Eisai Inc.,s Aricept® ... patients. TWi Pharmaceuticals is preparing to launch ... subsidiary, TWi Pharmaceuticals USA , at ...
Breaking Medicine Technology:Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 3Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 4Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 5Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 6Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 7Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 8Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 9Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 10Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 11Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 12Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 13Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 14Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 15Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 16Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 17Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 18Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 19Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 20Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 21Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 22
... , , MEMPHIS, Tenn. , Jan. 20 ... SN) Orthopaedics business is making available this week more than $2 ... in the treatment of survivors of last week,s earthquake in Haiti ... range of orthopedic surgical resources used to treat bone fractures. , ...
... Fla. , Jan. 20 Roper Industries, ... for the fourth quarter of 2009, ended December 31, 2009 , ... 2010 .  A conference call to discuss these results has been scheduled ... .  The call can be accessed via webcast or by dialing +1 ...
Cached Medicine Technology:Smith & Nephew Orthopaedics Begins Distribution to Haiti of Trauma Implants and Instruments 2Smith & Nephew Orthopaedics Begins Distribution to Haiti of Trauma Implants and Instruments 3
(Date:10/30/2014)... Seattle, WA (PRWEB) October 30, 2014 Sound ... their decision infographic that will assist people any time they ... people discover the right answer by leading them through a ... a resolution to their initial query. , There are many ... or not to use an answering service . This ...
(Date:10/30/2014)... WEDNESDAY, Oct. 29, 2014 (HealthDay News) -- Scientists who ... the laboratory say their breakthrough could provide a new ... of stomach diseases. The team used human pluripotent ... cell in the body -- to grow the functional ... bacteria, a major cause of ulcers and stomach ...
(Date:10/30/2014)... HealthDay Reporter WEDNESDAY, Oct. 29, ... bad for your health, a new study reports. Previous ... strengthen bones and prevent osteoporosis. These benefits to bone health ... of a healthy diet. But this new study found ... or women from bone fractures, and was linked to an ...
(Date:10/30/2014)... News) -- Eating a low-carb, high-fat diet could help ... new research. A review of five studies ... focuses on foods like bacon, eggs, heavy cream, butter, ... adults whose condition doesn,t improve with medication. "We ... with epilepsy whose seizures are not stopped by medications," ...
(Date:10/30/2014)... (HealthDay News) -- A new vaccine that could help ... approved by the U.S. Food and Drug Administration on ... the ages of 10 and 25 from invasive meningococcal ... bacteria. The bacteria can infect the bloodstream (sepsis) ... brain. It is a leading cause of bacterial meningitis, ...
Breaking Medicine News(10 mins):Health News:Sound Telecom Produces Decision Infographic to Aid Businesses 2Health News:Is Milk Your Friend or Foe? 2Health News:Is Milk Your Friend or Foe? 3Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 3Health News:FDA Approves New Vaccine to Protect Against Meningitis 2
... (HealthDay News) -- Workers with chronic low back pain can ... approach to care instead of traditional medical care, a new ... burden in developed countries, with 93 percent of the losses ... reason, researchers in the Netherlands tested a new approach among ...
... presented today at the annual meeting of the Radiological Society ... in the body of a human drug courier, known as ... from South America is making its way to Europe through ... of Berne and Institute of Forensic Medicine of Berne in ...
... and bottles of over-the-counter (OTC) medicines for children in the ... and follow, according to a study in the December 1 ... an unacceptable amount of inconsistency in labels and measuring devices ... MD, assistant professor of pediatrics at NYU School of Medicine ...
... able to use medical means to restrict the growth of ... at home? A working group convened to discuss the ethical ... an article in the Hastings Center Report . Personal ... or speak -- accompany the article Growth attenuation is ...
... Nov. 30 (HealthDay News) -- Patients have better outcomes ... a new review. The researchers analyzed 298 studies ... led to improved outcomes in a number of important ... and lower cholesterol. Pharmacist participation in patient care ...
... -- Primary school children cannot accurately estimate the speed of ... a new study. "This is not a matter of ... visual detection mechanisms," John Wann, lead researcher and a professor ... of London, said in a university news release. ...
Cached Medicine News:Health News:Workers With Low Back Pain Benefit From Integrated Care 2Health News:CT best at uncovering drug mule payload 2Health News:Instructions on over-the-counter medications for children are found to be confusing 2Health News:Recommendations issued on controversial 'Ashley' procedure for disabled children 2Health News:Kids Can't Accurately Judge Speed of Approaching Cars: Study 2
... The SR™ Hand Implant System utilizes ... and knee joint replacements. The SR™ ... available in other prostheses including minimal bone ... eroded cartilaginous articular surfaces, retention and/or repositioning ...
For use in implant resection arthroplasty of the trapeziometacarpal joint in cases of rheumatoid, degenerative or post-traumatic arthritis....
The efficient choice for small joint replacement technology -- the Ascension Silicone MCP features a similar design to our PyroCarbon MCP and utilizes the same instrumentation for intra-operative fle...
... Hand Implant System utilizes the same proven ... replacements. The SR™ Hand Implant System ... prostheses including minimal bone resection, surface replacement ... surfaces, retention and/or repositioning of the ligamentous ...
Medicine Products: